EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
<!-- Name:DistributionId Value:1000781638 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
AVT04
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed…
The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory conditions REYKJAVIK, Iceland and…